Lipoprotein(a). The Cardiovascular Risk Factor No One Told You About.

One in five adults carries a lipoprotein(a) level high enough to independently double their cardiovascular risk. The overwhelming majority have never been tested for it. It does not appear on the standard lipid panel ordered at your annual physical. It does not respond to the lifestyle interventions your physician will recommend if your cholesterol is high. And until very recently, there was no pharmacological treatment available to lower it. That last point is changing rapidly, which means the window for getting tested, understanding your number, and positioning yourself for emerging therapies is open right now.

The Mechanism

Lipoprotein(a), written as Lp(a) and pronounced “LP little a,” is structurally distinct from the LDL particle most people know about, though it begins with the same core architecture. At its center sits a lipid-rich sphere containing cholesterol esters and triglycerides, surrounded by a phospholipid shell. On the surface of that shell sits apolipoprotein B-100 (ApoB-100), the same structural protein that defines all LDL particles and serves as the primary ligand for LDL receptor binding. So far, this looks like standard LDL.

What makes Lp(a) categorically different is the covalent attachment of a second protein: apolipoprotein(a), or apo(a). This protein is encoded by the LPA gene on chromosome 6q26-27 and is unique to humans, hedgehogs, and Old World primates. It is tethered to ApoB-100 by a single disulfide bond. The resulting particle is larger, more complex, and biochemically more dangerous than LDL alone.

The critical feature of apolipoprotein(a) is its structural resemblance to plasminogen. Plasminogen is the precursor to plasmin, the enzyme responsible for dissolving blood clots through fibrinolysis. The similarity is not superficial: apo(a) contains multiple copies of kringle domains, specifically kringle IV type 2 repeats, along with a kringle V domain, all of which share strong structural homology with the kringle domains in plasminogen. Because of this structural mimicry, Lp(a) competes with plasminogen for binding sites on fibrin and on endothelial cell surfaces. The competition is physiologically significant. When Lp(a) occupies plasminogen binding sites, plasmin generation is reduced. Clots form normally but dissolve more slowly. A thrombus that develops on a ruptured atherosclerotic plaque persists longer. The window during which that clot can cause a myocardial infarction or stroke is extended. 5 / Solid

The atherogenicity of Lp(a) operates through a second, independent pathway. Lp(a) particles are unusually rich in oxidized phospholipids (OxPL). These OxPL molecules are biologically active: they bind to pattern recognition receptors on macrophages and endothelial cells, triggering inflammatory signaling cascades. OxPL carried by Lp(a) promote the recruitment of inflammatory monocytes to the arterial wall, drive macrophage differentiation into foam cells, and accelerate the formation of atherosclerotic plaque. The Lp(a) particle itself, because of its small size relative to some LDL fractions and because it is not efficiently cleared by LDL receptors, penetrates the arterial intima and deposits directly within developing plaques.

The combined result is a particle that builds plaque in the arterial wall and simultaneously makes the clotting response to a ruptured plaque more severe. This is why the cardiovascular risk associated with elevated Lp(a) is not simply additive to LDL risk: it operates through entirely different biological mechanisms, which is why lowering LDL does not lower Lp(a) risk, and why someone with well-controlled LDL can still carry a substantial residual cardiovascular risk if their Lp(a) is high.

The genetic architecture of Lp(a) levels reinforces this picture. Plasma Lp(a) concentrations are 80 to 90 percent determined by inherited variation in the LPA gene, principally by the number of kringle IV type 2 repeats in the apo(a) protein. Individuals who inherit isoforms with fewer kringle repeats produce smaller apo(a) proteins that are secreted more efficiently by the liver, resulting in higher plasma concentrations. Individuals with more repeats produce larger proteins that are processed and secreted less efficiently, resulting in lower plasma concentrations. The relationship between isoform size and plasma level is robust and largely unaffected by environmental factors. 5 / Solid

What the Evidence Shows

The foundational epidemiological evidence for Lp(a) as an independent cardiovascular risk factor comes from the Copenhagen General Population Study, reported by Kamstrup and colleagues in JAMA in 2010. This prospective analysis followed 69,369 individuals from the general Danish population with no prior cardiovascular disease. After adjusting for age, sex, smoking, diabetes, hypertension, LDL cholesterol, HDL cholesterol, and body mass index, individuals with Lp(a) levels in the highest decile (at or above 50 mg/dL) had a hazard ratio for myocardial infarction of 1.92 (95% CI, 1.59 to 2.31) compared with those in the lowest quintile (below 5 mg/dL). The risk increased continuously across Lp(a) levels and was present across all strata of LDL cholesterol, including in individuals with otherwise low or well-controlled LDL. 5 / Solid

The same study found elevated hazard ratios for ischemic heart disease (HR 1.39; 95% CI, 1.23 to 1.57 in the highest versus lowest quintile) and for ischemic stroke (HR 1.36; 95% CI, 1.04 to 1.79). The investigators also demonstrated a population attributable fraction: they estimated that approximately 20 percent of the excess cardiovascular risk in the cohort could be attributed to Lp(a) elevation above 50 mg/dL. The magnitude of that fraction matters because it means Lp(a) is not a rare or exotic risk factor with small population impact. It is a common risk factor with large individual and population-level consequences.

The question of causality, not merely association, was addressed by Clarke and colleagues in a Mendelian randomization study published in Nature Genetics in 2009. Mendelian randomization uses naturally occurring genetic variants as proxies for lifelong exposure to a risk factor, effectively simulating a randomized controlled trial that would be impossible to conduct in humans. The study used LPA gene variants associated with higher Lp(a) levels as the instrumental variable and examined coronary artery disease outcomes in approximately 24,000 individuals from the Ottawa Heart Study and three additional replication cohorts. Individuals carrying LPA variants associated with a 3.6 mg/dL higher Lp(a) had an odds ratio for coronary artery disease of 1.16 (95% CI, 1.11 to 1.22) per allele. Because the genetic exposure is randomly allocated at conception and cannot be confounded by lifestyle, diet, or socioeconomic factors, this analysis provides strong evidence that the relationship is causal, not merely correlational. 5 / Solid

Subsequent Mendelian randomization analyses have extended this finding. A 2019 meta-analysis by Burgess and colleagues in JAMA Cardiology, pooling data from genome-wide association studies including over 460,000 individuals, confirmed that genetically predicted Lp(a) is associated with coronary artery disease risk in a dose-response manner consistent with a causal relationship. The odds ratio per standard deviation increase in genetically predicted Lp(a) was 1.27 (95% CI, 1.24 to 1.30) for coronary artery disease and 1.10 (95% CI, 1.05 to 1.14) for stroke.

The INTERHEART study, a case-control study of 15,152 acute myocardial infarction cases and 14,820 controls across 52 countries published by Yusuf and colleagues in The Lancet in 2004, did not specifically report Lp(a) as a separate risk factor but provided the global context: the combination of traditional risk factors, including those that Lp(a) worsens through residual risk, accounted for more than 90 percent of population-attributable risk for MI. What INTERHEART documented was the degree to which cardiovascular risk is systematically under-measured in real-world clinical practice, a finding directly applicable to Lp(a), which is measured in fewer than 10 percent of eligible patients in most health systems despite guideline recommendations to do so.

The 2022 European Society of Cardiology lipid guidelines explicitly endorse Lp(a) measurement at least once in every adult, designating levels above 180 mg/dL (approximately 430 nmol/L) as conferring a lifetime cardiovascular risk equivalent to that of heterozygous familial hypercholesterolemia. The American College of Cardiology’s 2022 expert consensus document on lipid-lowering identifies elevated Lp(a) as a risk-enhancing factor warranting consideration in statin-eligibility decisions. Both bodies recommend that an elevated Lp(a) result should shift the threshold for intervention on every other modifiable risk factor downward.

Lp(a) and Calcific Aortic Valve Disease: A Second Independent Disease Pathway

Elevated lipoprotein(a) is not solely a risk factor for atherosclerotic cardiovascular disease. It is also the strongest known genetic risk factor for calcific aortic stenosis, a structurally distinct disease that operates through a partially overlapping but mechanistically separate pathway. This dual disease burden makes high Lp(a) qualitatively different from other lipid risk factors, which primarily accelerate coronary atherosclerosis.

Calcific aortic valve disease begins with the deposition of calcium within the leaflets of the aortic valve. Over years, the thickening leaflets restrict valve opening. When obstruction becomes hemodynamically significant, the left ventricle compensates through hypertrophy, and eventually forward cardiac output falls. Severe aortic stenosis is a mechanical problem with limited pharmacological solutions: the primary management is valve replacement, either surgical or transcatheter (TAVR). Understanding what causes the disease matters because it is common — affecting approximately 2 to 3 percent of adults over 65 — and because if its drivers are identified early, structural progression might be slowed or monitored before mechanical intervention becomes necessary.

The Lp(a) connection was established through Mendelian randomization. Larsson and colleagues, publishing in JAMA Cardiology in 2017, used LPA gene variants as the instrumental variable and examined aortic stenosis outcomes across more than 400,000 individuals. Genetically predicted higher Lp(a) was associated with an odds ratio of 1.50 per standard deviation increase for aortic stenosis, after adjustment for LDL cholesterol and other lipid fractions. Because genetic allocation is random at conception and cannot be confounded by lifestyle or medication use, this result provides strong evidence for a causal rather than merely associative relationship. 5 / Solid

The mechanism operates through the oxidized phospholipids (OxPL) carried on Lp(a) particles — the same molecules that accelerate coronary atherosclerosis. In the aortic valve leaflet, OxPL molecules bind to valvular interstitial cells and activate pro-calcific signaling pathways, including bone morphogenetic protein-2 (BMP-2), which promotes osteoblastic differentiation of valve cells. The leaflet becomes a site of active mineral deposition, driven by the same Lp(a)-carried OxPL that promote foam cell formation in the arterial wall simultaneously. Arsenault and colleagues demonstrated in JACC in 2014 that plasma OxPL levels, which track closely with Lp(a) levels, independently predicted the progression of aortic valve calcification on CT imaging in a prospective cohort study.

The clinical implication is specific. A man with elevated Lp(a) who presents in his 50s with a cardiac murmur or exertional fatigue should have a baseline echocardiogram that specifically evaluates aortic valve morphology and the presence of early leaflet calcification. The combination of high Lp(a) and aortic sclerosis on echo — thickening without hemodynamic obstruction — identifies a patient at substantially elevated risk for progression to clinically significant stenosis over the subsequent decade. This is a surveillance decision, not a treatment decision, but one that changes the monitoring schedule and increases the urgency of managing every other modifiable cardiovascular risk factor in parallel.

What to Do This Week

1. Ask for the test by name at your next appointment. Lp(a) is not on the standard lipid panel. You must request it separately. Say: “I have never had my Lp(a) measured. Current guidelines from the European Society of Cardiology and the American College of Cardiology recommend measuring it at least once in every adult. Can we add it to my next lab order?” It requires a single blood draw and is covered by most insurance plans when ordered alongside a standard lipid panel with any cardiovascular risk indication.

2. If your Lp(a) result is above 50 mg/dL, request a formal cardiovascular risk reassessment. This is not a conversation about lifestyle. It is a conversation about whether your LDL target, blood pressure target, and statin or ApoB-lowering therapy need to be more aggressive in light of a fixed, genetically determined background risk. Bring the number to your cardiologist or internist and ask: “How does this change the targets we are working toward on my other risk factors?”

3. If your Lp(a) is above 125 nmol/L (approximately 50 mg/dL), consider a formal evaluation for familial hypercholesterolemia. Very high Lp(a) and FH co-occur more commonly than by chance, and FH has its own set of specific management implications. A fasting lipid panel, ApoB level, and family history review are appropriate starting points. Your physician may refer you to a lipid specialist.

4. Get your first-degree relatives tested. Because Lp(a) is 80 to 90 percent genetically determined, each biological parent, sibling, and child of a high-Lp(a) individual has a meaningfully elevated probability of carrying a similar level. A single-page family health history documenting premature cardiovascular events (heart attack or stroke before age 55 in men, before age 65 in women) is sufficient grounds to recommend Lp(a) testing in relatives who have not already had it.

5. Register your result and follow the OCEAN(a)-OUTCOMES and Lp(a)HORIZON trial timelines. If you have a documented elevated Lp(a), you are in the population that emerging RNA-targeted therapies are designed for. Trial results are expected in 2025 to 2026. Ask your cardiologist or internist to flag your chart for notification when approved therapies become available, and ask whether you are a candidate for any currently enrolling clinical trials offering access to olpasiran or pelacarsen.

The standard lipid panel was designed in an era when LDL was the only lipid target with available pharmacotherapy, and the panel reflects that history rather than current knowledge. Lp(a) has been identified as a causal cardiovascular risk factor for more than three decades; the Copenhagen General Population Study quantifying its magnitude was published fifteen years ago; guideline bodies on both sides of the Atlantic have recommended routine measurement for years. The test costs less than fifty dollars when processed at a reference lab. The only thing between most middle-aged men and knowledge of their Lp(a) level is a physician remembering to order it. That is a solvable problem.